Skip to main content
SpringerLink
Log in

Data page

Public biotech in 2022 — the numbers

  • Data Page
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

  • 3 Altmetric

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Biotech IPO activity since 2011, showing the amount raised ($ millions) and the number of companies going public.
Fig. 2: NASDAQ biotech index over time.
Fig. 3: Number of biotech companies and employees by market capitalization.
Fig. 4: Public biotech company revenue, R&D spending and net profit or loss by market capitalization.

Author information

Authors and Affiliations

  1. Senior Editor, Nature Biotechnology https://www.nature.com/nbt/

    Laura DeFrancesco

  2. Turku, Finland

    Riku Lähteenmäki

Authors
  1. Laura DeFrancesco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Table

Supplementary Table 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L., Lähteenmäki, R. Public biotech in 2022 — the numbers. Nat Biotechnol 41, 1185 (2023). https://doi.org/10.1038/s41587-023-01923-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01923-4

  • Springer Nature America, Inc.

Search

Navigation